Recommendations on screening for lung cancer

Lewin, Gabriela; Morissette, Kate; Dickinson, James A; Bell, Nathanial; Bacchus, Michael; Singh, Harminder; Tonelli, Marcello; A, Jaramillo Garcia

doi:10.1503/cmaj.151421

Cited by 131 publications

(35 citation statements)

References 16 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Guidelines in Canada and the United States now recommend LDCT screening for high risk individuals (5)(6)(7)(8). In Ontario, primary care physicians are instrumental in screening for other types of cancer, specifically cervical, colorectal, breast cancer.…”

Section: The National Lung Screening Trial (Nlst) In the United Statementioning

confidence: 99%

“…(https://www.cancercareontario.ca/en/get-checked-cancer). For primary care providers (PCPs), there may be challenges in identifying patients who are eligible for LDCT screening since criteria include duration and amount of smoking as well as age (5)(6)(7)(8). Although several US studies have reported PCP interest in LDCT screening (9,10), we did not identify Canadian data on PCP preferences for involvement in an organized LDCT screening program.…”

Section: The National Lung Screening Trial (Nlst) In the United Statementioning

confidence: 99%

See 1 more Smart Citation

Primary care providers’ views on a future lung cancer screening program

et al. 2018

View full text Add to dashboard Cite

Background The National Lung Screening Trial demonstrated that screening with low-dose computed tomography significantly reduces mortality from lung cancer in high-risk individuals. Objective To describe the role preferences and information needs of primary care providers (PCPs) in a future organized lung cancer screening program. Methods We purposively sampled PCPs from diverse health regions of Ontario and from different practice models including family health teams and community health centres. We also recruited family physicians with a leadership role in cancer screening. We used focus groups and a nominal group process to identify informational priorities. Two analysts systematically applied a coding scheme to interview transcripts. Results Four groups were held with 34 providers and administrative staff [28 (82%) female, 21 (62%) physicians, 7 (20%) other health professionals and 6 (18%) administrative staff]. PCPs and staff were generally positive about a potential lung cancer screening program but had variable views on their involvement. Informational needs included evidence of potential benefits and harms of screening. Most providers preferred that a new program be modelled on positive features of an existing breast cancer screening program. Lung cancer screening was viewed as a new opportunity to counsel patients about smoking cessation. Conclusions The development of a future lung cancer screening program should consider the wide variability in the roles that PCPs preferred. An explicit link to existing smoking cessation programs was seen as essential. As providers had significant information needs, learning materials and opportunities should be developed with them.

show abstract

Section: The National Lung Screening Trial (Nlst) In the United Statementioning

confidence: 99%

Section: The National Lung Screening Trial (Nlst) In the United Statementioning

confidence: 99%

Primary care providers’ views on a future lung cancer screening program

et al. 2018

View full text Add to dashboard Cite

show abstract

“…13 Accurate prognosis is also critical for NSCLC patients due to the fact that most NSCLC patients are diagnosed at late stages. 2,3 Therefore, accurate prognosis may guide the individualized treatment program, thereby prolonging patients' survival. We showed that low MIR503HG level in NSCLC tissues was closely associated with the poor survival of NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

“…1 The major cause of the high mortality rate of lung cancer is the low early diagnostic rate. 2,3 Therefore, most lung cancer patients are diagnosed at advanced stages, which are not suitable for radical surgery. 4 As the most common subtypes of lung cancer, non-small cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases.…”

Section: Introductionmentioning

confidence: 99%

<p>LncRNA MIR503HG Inhibits Non-Small Cell Lung Cancer Cell Proliferation by Inducing Cell Cycle Arrest Through the Downregulation of Cyclin D1</p>

Zhai

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: LncRNA MIR503HG has been reported to participate in liver cancer and ALK-negative anaplastic large-cell lymphoma, while its role in non-small cell lung cancer (NSCLC) is unknown. We therefore investigated the functions of lncRNA MIR503HG in NSCLC. Methods: MIR503HG expression in paired cancer and non-cancer tissues from NSCLC patients was analyzed by RT-qPCR. The interaction between cyclin D1 and MIR503HG was analyzed by overexpression experiments. Cell cycle analysis was performed by flow cytometry. Cell proliferation was analyzed by CCK-8 assay. Results: MIR503HG was downregulated in NSCLC and low levels of MIR503HG were associated with poor survival. In contrast, cyclin D1 was upregulated in NSCLC, and cyclin D1 and MIR503HG were inversely correlated. In NSCLC cells, overexpression experiments revealed that MIR503HG functioned as an upstream inhibitor of cyclin D1. MIR503HG overexpression led to G1 cell cycle arrest, while overexpression of cyclin D1 attenuated the effects of MIR503HG overexpression. Similarly, MIR503HG overexpression resulted in reduced cell proliferation rate, while overexpression of cyclin D1 caused the increased cell proliferation rate and attenuated effects of MIR503HG overexpression. Conclusion: MIR503HG inhibits NSCLC cell proliferation by inducing cell cycle arrest through the downregulation of cyclin D1.

show abstract

“…First of all, the traditional chest radiography (with or without sputum cytology) has been denied as screening techniques for lung cancer [21, 22]. RCTs in the 1960s and 1970s found that chest X-ray screening did not reduce the mortality for high-risk individuals [23].…”

Section: Discussionmentioning

confidence: 99%

Necessity of organized low-dose computed tomography screening for lung cancer: From epidemiologic comparisons between China and the Western nations

et al. 2016

View full text Add to dashboard Cite

ObjectivesTo compare the proportion of stage I lung cancer and population mortality in China to those in U.S. and Europe where lung cancer screening by low-dose computed tomography (LDCT) has been already well practiced.MethodsThe proportions of stage I lung cancer in LDCT screening population in U.S. and Europe were retrieved from NLST and NELSON trials. The general proportion of stage I lung cancer in China was retrieved from a rapid meta-analysis, based on a literature search in the China National Knowledge Infrastructure database. The lung cancer mortality and prevalence of China, U.S. and Europe was retrieved from Globocan 2012 fact sheet. Mortality-to-prevalence ratio (MPR) was applied to compare the population survival outcome of lung cancer.ResultsThe estimated proportion of stage I lung cancer in China is merely 20.8% among hospital-based cross-sectional population, with relative ratios (RRs) being 2.40 (95% CI 2.18–2.65) and 2.98 (95% CI 2.62–3.38) compared by LDCT-screening population in U.S. and Europe trials, respectively. MPR of lung cancer is as high as 58.9% in China, with RRs being 0.46 (95% CI 0.31–0.67) and 0.58 (95% CI 0.39–0.85) compared by U.S. and Europe, respectively.ConclusionsBy the epidemiological inference, the LDCT mass screening might be associated with increasing stage I lung cancer and therefore improving population survival outcome. How to translate the experiences of lung cancer screening by LDCT from developed counties to China in a cost-effective manner needs to be further investigated.

show abstract

Recommendations on screening for lung cancer

Cited by 131 publications

References 16 publications

Primary care providers’ views on a future lung cancer screening program

Primary care providers’ views on a future lung cancer screening program

<p>LncRNA MIR503HG Inhibits Non-Small Cell Lung Cancer Cell Proliferation by Inducing Cell Cycle Arrest Through the Downregulation of Cyclin D1</p>

Necessity of organized low-dose computed tomography screening for lung cancer: From epidemiologic comparisons between China and the Western nations

Contact Info

Product

Resources

About